Melanotan-2 (MT-2) is a synthetic melanocortin analog studied for libido support, skin pigmentation, and appetite modulation. Physician-reviewed. Prescription required.
MT-2 (often called Melanotan-2) is a synthetic peptide derived from Alpha-Melanocyte-Stimulating Hormone. It acts primarily through the central melanocortin system to influence sexual arousal, autonomic nervous system activity, and dopamine signaling. Its effects are centrally mediated in the brain rather than peripheral vascular mechanisms, which distinguishes it from drugs like PDE-5 inhibitors.
Individual outcomes may differ. This protocol is not intended to diagnose, treat, cure, or prevent any disease.
| Mechanism | Physiological Effect |
|---|---|
| Melanocortin receptor agonism (MC3R/MC4R) | Activation of sexual arousal circuits |
| Hypothalamic signaling | Increased libido and sexual motivation |
| Dopamine pathway activation | Enhanced reward and sexual desire |
| Autonomic nervous system activation | Increased genital blood flow |
| Indirect nitric oxide signaling | Facilitation of erectile response |
| Appetite pathway modulation | Secondary melanocortin effects |
Your physician will determine eligibility based on your complete health intake. The following profiles are commonly associated with Melanotan-2 protocol candidates in clinical practice:
Hypoactive Sexual Desire (Women)
Premenopausal women with physician-confirmed HSDD seeking FDA-cleared or physician-supervised Melanotan-2 therapy.
Sexual Dysfunction (Men)
Men with sexual dysfunction unresponsive to or not suitable for PDE5 inhibitor therapy, under physician supervision.
Combination Therapy
Individuals whose physician has determined Melanotan-2 complementary to existing vascular or hormonal therapies.
Hormonal / Menopause Context
Individuals with sexual wellness concerns in hormonal transition contexts, under physician oversight.
Determine your candidacy
A physician will review your intake and make eligibility determination within 24–48 hours.
All outcome language below reflects what has been observed in clinical and preclinical settings. Individual outcomes may differ significantly. These are not guarantees.
Dosing is determined individually by your assigned physician. The following represents typical ranges discussed in clinical literature. Do not self-administer or adjust dosing without physician guidance.
Typical Range
1.75 mg per dose (FDA-approved dose for women)
Administration
Subcutaneous injection or nasal spray (physician-determined)
Duration
As-needed or cyclic protocol (physician-determined)
Frequency
As needed, no more than once per 24 hours (physician-determined)
These ranges are indicative only. Your physician will prescribe the specific dose and schedule appropriate for your clinical profile.
Physician consultation — Virtual intake review and protocol consultation with your assigned NP/MD
Valid prescription — Issued by your attending physician upon protocol approval
Pharmacy-dispensed compound — Dispensed by our licensed 503A compounding pharmacy partner
Follow-up check-in — Physician review at protocol midpoint; reorder pathway established
Your physician will review your complete health history before determining eligibility. The following are commonly reviewed clinical considerations.